Chemotherapy Induced Neutropenia Drug Market

Chemotherapy Induced Neutropenia Drug Market contains market size and forecasts of Chemotherapy Induced Neutropenia Drug in global, including the following market information:
Global Chemotherapy Induced Neutropenia Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Chemotherapy Induced Neutropenia Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Chemotherapy Induced Neutropenia Drug companies in 2021 (%)
The global Chemotherapy Induced Neutropenia Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
F-627 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chemotherapy Induced Neutropenia Drug include BeyondSpring Pharmaceuticals Inc, Biocon Ltd, Bolder Biotechnology Inc, Cellerant Therapeutics Inc, Chong Kun Dang Pharmaceutical Corp, Cinfa Biotech SL, Dr. Reddy's Laboratories Ltd, Gene Techno Science Co Ltd and Generon (Shanghai) Corp Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chemotherapy Induced Neutropenia Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy Induced Neutropenia Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Chemotherapy Induced Neutropenia Drug Market Segment Percentages, by Type, 2021 (%)
F-627
BBT-018
Filgrastim
GW-003
NLA-101
Others
Global Chemotherapy Induced Neutropenia Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Chemotherapy Induced Neutropenia Drug Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Chemotherapy Induced Neutropenia Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Chemotherapy Induced Neutropenia Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy Induced Neutropenia Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Chemotherapy Induced Neutropenia Drug revenues share in global market, 2021 (%)
Key companies Chemotherapy Induced Neutropenia Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Chemotherapy Induced Neutropenia Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cinfa Biotech SL
Dr. Reddy's Laboratories Ltd
Gene Techno Science Co Ltd
Generon (Shanghai) Corp Ltd
Genexine Inc
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
Intas Pharmaceuticals Ltd
Lupin Ltd
Mycenax Biotech Inc
Myelo Therapeutics GmbH
Nohla Therapeutics Inc
Octapharma AG
Pangen Biotech Inc.
Pfenex Inc
Pfizer Inc
Reliance Life Sciences Pvt Ltd
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd